| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(01)07098-2 |
| P698 | PubMed publication ID | 11755609 |
| P2093 | author name string | E Steiner | |
| A H Aastveit | |||
| G Walldius | |||
| I Holme | |||
| I Jungner | |||
| W Kolar | |||
| P2860 | cites work | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor | Q32063024 | ||
| Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) | Q34467101 | ||
| Apolipoprotein concentrations during treatment and recurrent coronary artery disease events | Q40739184 | ||
| Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease | Q40753215 | ||
| Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study | Q40932772 | ||
| Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females | Q43587857 | ||
| Atherogenicity of triglyceride-rich lipoproteins | Q44450469 | ||
| Treatment of dyslipidemia: room for improvement? | Q45106430 | ||
| LDL size and risk of coronary heart disease in elderly men and women | Q47253662 | ||
| Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography | Q47810153 | ||
| Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study | Q71971744 | ||
| Relationship between HDL-cholesterol and apolipoprotein Al and the severity of coronary artery disease | Q72051659 | ||
| The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease | Q72235665 | ||
| VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial | Q73085857 | ||
| Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) | Q73419520 | ||
| Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention | Q77575506 | ||
| Thrombogenic factors and recurrent coronary events | Q77756586 | ||
| P433 | issue | 9298 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| P304 | page(s) | 2026-2033 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study | |
| P478 | volume | 358 |
| Q90018009 | A clinical prescription for heart health in midlife women |
| Q37288388 | A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. |
| Q33933946 | A modified formula for calculating low-density lipoprotein cholesterol values |
| Q36843460 | A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL₃+IDL]). |
| Q61445257 | A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia |
| Q44480091 | A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus |
| Q43043483 | Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. |
| Q44157908 | Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes |
| Q37327222 | Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. |
| Q47859533 | Advances in quantifying apolipoproteins using LC-MS/MS technology: implications for the clinic |
| Q37434556 | Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol |
| Q37121372 | Age and follow-up time affect the prognostic value of the ECG and conventional cardiovascular risk factors for stroke in adult men |
| Q40027463 | Aggregation of lipoprotein and inflammatory parameters in families with a history of premature myocardial infarction: the Tallinn myocardial infarction study |
| Q45138303 | Ajuga iva aqueous extract improves reverse cholesterol transport in streptozotocin-induced diabetic rat. |
| Q34532031 | An equation to estimate the concentration of serum apolipoprotein B. |
| Q47817694 | Analysis of traditional and emerging risk factors in premenopausal women with coronary artery disease: A pilot-scale study from North India. |
| Q41998559 | Antiatherosclerotic Potential of Active Principle Isolated from Eugenia jambolana in Streptozotocin-Induced Diabetic Rats |
| Q37653755 | Antiobesity and vasoprotective effects of resveratrol in apoE-deficient mice |
| Q36395720 | Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. |
| Q37679076 | Apo B/Apo A-I Ratio is Statistically A Better Predictor of Cardiovascular Disease (CVD) than Conventional Lipid Profile: A Study from Kathmandu Valley, Nepal |
| Q43109265 | Apo-B/AI ratio identifies cardiovascular risk in childhood: the Australian Aboriginal Birth Cohort study |
| Q49223170 | ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels |
| Q36683234 | ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity |
| Q36562244 | Apolipoprotein A-I and risk for cardiovascular diseases |
| Q42957452 | Apolipoprotein A1 gene polymorphism (G-75A and C+83T) in patients with myocardial infarction: a pilot study in a north Indian population |
| Q38585585 | Apolipoprotein A1, B levels, and their ratio and the risk of a first stroke: a meta-analysis and case-control study |
| Q42796829 | Apolipoprotein B (apoB) more closely related to subclinical atherosclerosis than non‐HDL cholesterol and LDL cholesterol |
| Q35868249 | Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes |
| Q35640331 | Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy |
| Q51322796 | Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study. |
| Q44419464 | Apolipoprotein B and non-high density lipoprotein cholesterol and the risk of coronary heart disease in Chinese |
| Q51790183 | Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up. |
| Q37267152 | Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites |
| Q64256097 | Apolipoprotein B correlates with intra-plaque necrotic core volume in stable coronary artery disease |
| Q40076502 | Apolipoprotein B is associated with carotid atherosclerosis progression independent of individual cholesterol measures in a 9-year prospective study of Multi-Ethnic Study of Atherosclerosis participants |
| Q34853434 | Apolipoprotein B is highly associated with the risk of coronary heart disease as estimated by the Framingham risk score in healthy Korean men. |
| Q42796828 | Apolipoprotein B, non‐HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk |
| Q51385270 | Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein. |
| Q64933119 | Apolipoprotein B/A1 and risk of cardiovascular disease. |
| Q51385015 | Apolipoprotein B/A1 ratio is associated with free androgen index and visceral adiposity and may be an indicator of metabolic syndrome in male children and adolescents. |
| Q44557222 | Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects |
| Q45014749 | Apolipoprotein B/apolipoprotein A-I ratio and apolipoprotein B: long-term predictors of myocardial infarction in initially healthy middle-aged men--a 13-year follow-up |
| Q55002489 | Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. |
| Q85916660 | Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients |
| Q28278173 | Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis |
| Q51463602 | Apolipoprotein E and lipoprotein lipase gene polymorphisms interaction on the atherogenic combined expression of hypertriglyceridemia and hyperapobetalipoproteinemia phenotypes. |
| Q46681511 | Apolipoprotein E gene polymorphism and serum lipid levels in the Guangxi Hei Yi Zhuang and Han populations |
| Q64059860 | Apolipoprotein Profiles in Very Preterm and Term-Born Preschool Children |
| Q37594701 | Apolipoprotein measurements: is more widespread use clinically indicated? |
| Q36966031 | Apolipoprotein polymorphisms and familial hypercholesterolemia |
| Q92483764 | Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia |
| Q88167231 | Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D |
| Q33572201 | Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee |
| Q36573819 | Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes |
| Q57293920 | Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up |
| Q36455892 | Apolipoproteins AI and B as therapeutic targets |
| Q37526539 | Apolipoproteins AI/B/E gene polymorphism and their plasma levels in patients with coronary artery disease in a tertiary care-center of Eastern India |
| Q42576522 | Apolipoproteins and diabetic retinopathy |
| Q44014244 | Apolipoproteins and prediction of fatal myocardial infarction |
| Q46954471 | Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack |
| Q43188342 | Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease |
| Q44350203 | Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment |
| Q46274924 | Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). |
| Q74227048 | Apolipoprotiens and prediction of fatal myocardial infarction |
| Q36874560 | Apoprotein B/Apoprotein A-1 Ratio and Mortality among Prevalent Dialysis Patients |
| Q40623022 | Approach to lipoprotein management in 2001 National Cholesterol Guidelines |
| Q33737082 | Are there socioeconomic inequalities in cardiovascular risk factors in childhood, and are they mediated by adiposity? Findings from a prospective cohort study |
| Q38950900 | Assessing Cardiovascular Risk and Testing in Type 2 Diabetes |
| Q40169397 | Assessing the clinical utility of biomarkers in medicine |
| Q51095441 | Assessment of serum apolipoprotein B and apolipoprotein A-1 and their ratio in healthy full term small for gestational age newborns. |
| Q42116401 | Association Between Apo Lipoprotein B Levels at Admission of Patients and Short-term Morbidity and Mortality After Myocardial Infarction |
| Q36801946 | Association between Osteocalcin, Metabolic Syndrome, and Cardiovascular Risk Factors: Role of Total and Undercarboxylated Osteocalcin in Patients with Type 2 Diabetes |
| Q37045608 | Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories |
| Q36547075 | Association between dietary flavanones intake and lipid profiles according to the presence of metabolic syndrome in Korean women with type 2 diabetes mellitus |
| Q34806349 | Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study |
| Q37061355 | Association between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality |
| Q37140846 | Association of Serum Apolipoprotein B with the Increased Risk of Diabetes in Korean Men. |
| Q51246459 | Association of Spicy Food Consumption Frequency with Serum Lipid Profiles in Older People in China. |
| Q36318265 | Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples |
| Q37441909 | Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population |
| Q35667553 | Association of apolipoprotein B, LDL-C and vascular stiffness in adolescents with type 1 diabetes. |
| Q37222153 | Association of apolipoprotein B, apolipoprotein A, and the its ratio with body fat distribution |
| Q36841091 | Association of apolipoprotein b/apolipoprotein A1 ratio and coronary artery stenosis and plaques detected by multi-detector computed tomography in healthy population |
| Q48585134 | Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study |
| Q47943902 | Association of serum osteocalcin levels with major adverse cardiovascular events: A 4.4-year retrospective cohort study |
| Q47171948 | Association of sleep duration with apolipoproteins and the apolipoprotein B/A1 ratio: the China health and nutrition survey |
| Q44044983 | Association of the apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein cholesterol with insulin resistance in a Chinese population with abdominal obesity |
| Q39763799 | Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study |
| Q55009946 | Associations Between Dietary Antioxidant Intake and Markers of Atherosclerosis in Middle-Aged Women From North-Western Algeria. |
| Q36455898 | Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies |
| Q33684013 | Associations between prediagnostic blood glucose levels, diabetes, and glioma. |
| Q92081559 | Associations between serum apolipoproteins, urinary albumin excretion rate, estimated glomerular filtration rate, and diabetic retinopathy in individuals with type 2 diabetes |
| Q44221049 | Associations of genetic polymorphisms in the renin-angiotensin system with central aortic and ambulatory blood pressure in type 2 diabetic patients. |
| Q50863344 | Atherogenic dyslipidaemic profiles associated with the development of Type 2 diabetes: a 3.1-year longitudinal study. |
| Q48342012 | Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women : A 10-year follow-up. |
| Q36596894 | Atherogenic lipid profiles and its management in patients with rheumatoid arthritis |
| Q36170806 | Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? |
| Q33306319 | Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. |
| Q42759283 | Atherosclerotic markers in obese and nonobese children and relationship with nighttime hypertension |
| Q84971211 | Beyond statin therapy: a review of the management of residual risk in diabetes mellitus |
| Q36738090 | Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools |
| Q46259107 | Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acids |
| Q26782354 | Biological and Nutritional Properties of Palm Oil and Palmitic Acid: Effects on Health |
| Q35862709 | Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study |
| Q38691517 | Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort |
| Q31139036 | Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths |
| Q46691226 | Body mass index and high-density lipoproteins in Cherokee Indian children and adolescents |
| Q34566524 | Both serum apolipoprotein B and the apolipoprotein B/apolipoprotein A-I ratio are associated with carotid intima-media thickness |
| Q44897662 | Breastmilk feeding and lipoprotein profile in adolescents born preterm: follow-up of a prospective randomised study |
| Q36371060 | CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis |
| Q38335713 | Cardiometabolic risk factors as apolipoprotein B, triglyceride/HDL-cholesterol ratio and C-reactive protein, in adolescents with and without obesity: cross-sectional study in middle class suburban children |
| Q37424605 | Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? |
| Q56515974 | Cardiovascular events in patients under age fifty with early findings of elevated lipid and glucose levels - The AMORIS study |
| Q34600040 | Cardiovascular risk according to plasma apolipoprotein and lipid profiles in a Canadian First Nation. |
| Q37716374 | Cardiovascular risk assessment of dyslipidemic children: analysis of biomarkers to identify monogenic dyslipidemia. |
| Q37022802 | Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms |
| Q45198801 | Cardiovascular risk factors in overweight and obese Chinese children: a comparison of weight-for-height index and BMI as the screening criterion |
| Q33859039 | Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study |
| Q56659929 | Cholesterol screening and the Gold Effect |
| Q46504504 | Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. |
| Q92977270 | Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study |
| Q41146250 | Chronic kidney disease and 10-year risk of cardiovascular death |
| Q40238562 | Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study |
| Q36037541 | Circulating, imaging, and genetic biomarkers in cardiovascular risk prediction |
| Q38165804 | Clinical and biological relevance of statin-mediated changes in HDL metabolism |
| Q34990615 | Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity |
| Q40789871 | Clinical significance of serum apolipoproteins as a predictor of coronary heart disease risk in Korean men. |
| Q34403350 | Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance |
| Q34417470 | Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy |
| Q92628084 | Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis |
| Q44265033 | Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease |
| Q35106600 | Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and inflammation biomarkers in hypertensive patients with dyslipidemia |
| Q25257849 | Comparison of isocaloric very low carbohydrate/high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk |
| Q24814804 | Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study |
| Q89742004 | Comparison of the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy and Rosuvastatin Monotherapy on Lipoprotein in Patients With Type 2 Diabetes: Multicenter Randomized Controlled Study |
| Q35605494 | Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) |
| Q38096921 | Comparison of therapeutic lipid target achievements among high-risk patients in Oman |
| Q35890892 | Compendium of genome-wide scans of lipid-related phenotypes: adding a new genome-wide search of apolipoprotein levels |
| Q46709605 | Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study |
| Q37291503 | Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population |
| Q90266705 | Consumption of a defined, plant-based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks |
| Q36343410 | Conventional and Advanced Lipid Parameters in Premature Coronary Artery Disease Patients in India |
| Q43267040 | Current state of hormone replacement therapy: the case for using trimegestone |
| Q35571245 | Decline in Coronary Mortality in Sweden between 1986 and 2002: Comparing Contributions from Primary and Secondary Prevention |
| Q44430812 | Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? |
| Q38141575 | Demystifying the management of hypertriglyceridaemia. |
| Q44599952 | Detection of Vascular Disease Risk in Women by Panoramic Radiography |
| Q28729748 | Determinants of aortic stiffness: 16-year follow-up of the Whitehall II study |
| Q54430137 | Determinants of risk factors of atherosclerosis in the postinfarction period: the Tallinn MI study. |
| Q37857864 | Diabetic dyslipidemia or 'diabetes lipidus'? |
| Q24535759 | Dietary fats, carbohydrate, and progression of coronary atherosclerosis in postmenopausal women |
| Q34564452 | Differential effect of corn oil-based low trans structured fat on the plasma and hepatic lipid profile in an atherogenic mouse model: comparison to hydrogenated trans fat. |
| Q39826326 | Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia |
| Q90364689 | Dyslipidemia and cardiovascular disease risk among the MASHAD study population |
| Q46884224 | Dyslipidemia and other cardiovascular risk factors in a Canadian First Nation pediatric population with type 2 diabetes mellitus |
| Q51629961 | Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. |
| Q44577765 | Effect of acute and chronic moderate alcohol consumption on fasted and postprandial lipemia in the rat. |
| Q50733664 | Effect of acute and chronic moderate red or white wine consumption on fasted and postprandial lipemia in the rat. |
| Q46981911 | Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study |
| Q36577724 | Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo |
| Q45895181 | Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study |
| Q42287403 | Effect of hydroalcoholic extract of Hypericum perforatum on selected traditional and novel biochemical factors of cardiovascular diseases and atherosclerotic lesions in hypercholesterolemic rabbits: A comparison between the extract and lovastatin |
| Q51494422 | Effect of hydroxycut intake on fasted and postprandial lipemia in rats. |
| Q28281870 | Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study |
| Q87580277 | Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease |
| Q35925241 | Effect of the 3'APOB-VNTR polymorphism on the lipid profiles in the Guangxi Hei Yi Zhuang and Han populations |
| Q44642211 | Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). |
| Q92248841 | Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies |
| Q43165990 | Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. |
| Q46901939 | Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients |
| Q44156647 | Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial |
| Q37247016 | Effects of isoflavones on lipid and apolipoprotein levels in patients with type 2 diabetes in Heilongjiang Province in China |
| Q46746525 | Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women |
| Q24650533 | Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit |
| Q92661921 | Elastic aortic wrap reduced aortic stiffness by partially alleviating the impairment of cholesterol efflux capacity in pigs |
| Q51809299 | Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. |
| Q44776392 | Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population |
| Q53161928 | Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. |
| Q44739256 | Estimation of VLDL, IDL, LDL, HDL2, apoA-I, and apoB from the Friedewald inputs--apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes |
| Q37435355 | Evaluation of Lipid Profile and Apolipoproteins in Essential Hypertensive Patients |
| Q33761674 | Evaluation of different formulas for LDL-C calculation |
| Q34307326 | Exercise improves immune function, antidepressive response, and sleep quality in patients with chronic primary insomnia |
| Q46055519 | Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice |
| Q50062280 | Extended Serum Lipid Profile Predicting Long-Term Survival in Patients Treated for Abdominal Aortic Aneurysms |
| Q50956427 | Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. |
| Q43873533 | Familial effects on survival after myocardial infarction: a registry-based sib-pair study |
| Q26828489 | Familial hypercholesterolemia: present and future management |
| Q36952948 | Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events |
| Q36317996 | Features of the metabolic syndrome and the risk of cardiovascular disease |
| Q33609025 | Fenugreek seed extract inhibit fat accumulation and ameliorates dyslipidemia in high fat diet-induced obese rats |
| Q34421046 | Fructosamine is a useful indicator of hyperglycaemia and glucose control in clinical and epidemiological studies--cross-sectional and longitudinal experience from the AMORIS cohort |
| Q36429561 | Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study. |
| Q53736294 | Gamma-glutamyltransferase activity as a surrogate biomarker of metabolic health status in young nondiabetic obese women. |
| Q37267076 | Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice |
| Q36455894 | Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease |
| Q36334462 | Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort |
| Q49796174 | Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort |
| Q46759075 | Growth before 2 years of age and serum lipids 60 years later: the Helsinki Birth Cohort study |
| Q33303679 | Growth environment and sex differences in lipids, body shape and diabetes risk |
| Q43297974 | Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). |
| Q38382763 | Health, Wellbeing and Social Sciences |
| Q58275954 | High blood hemoglobin concentration as risk factor of major atherosclerotic cardiovascular events in 114,159 healthy men and women in the Apolipoprotein MOrtality RISk study (AMORIS) |
| Q36376568 | High hydrostatic pressure extract of garlic increases the HDL cholesterol level via up-regulation of apolipoprotein A-I gene expression in rats fed a high-fat diet |
| Q40527056 | High prevalence of subclinical atherosclerosis in Brazilian postmenopausal women with low and intermediate risk by Framingham score |
| Q37147062 | High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease |
| Q42703667 | High throughput quantification of apolipoproteins A-I and B-100 by isotope dilution MS targeting fast trypsin releasable peptides without reduction and alkylation. |
| Q46564730 | High-density lipoprotein apolipoprotein A-I kinetics in obesity |
| Q38089776 | High-density lipoprotein: what is the best way to measure its antiatherogenic potential? |
| Q45269281 | Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. |
| Q46092744 | Homocysteine increases the risk associated with hyperlipidaemia. |
| Q43073625 | Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy |
| Q46461777 | How do conventional markers of lipid disorders compare with apolipoproteins? |
| Q28645890 | How, when, and why to use apolipoprotein B in clinical practice |
| Q51539332 | Human cytokine response to Texas crotaline envenomation before and after antivenom administration |
| Q45231827 | Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. |
| Q36527075 | Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan |
| Q40724787 | Impact of Apolipoprotein B on Hepatosteatosis in a Population Infected with Hepatitis C Virus: A Cross-Sectional Observational Study |
| Q35589699 | Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios |
| Q40313878 | Impact of follow-up time and re-measurement of the electrocardiogram and conventional cardiovascular risk factors on their predictive value for myocardial infarction |
| Q59265277 | Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer |
| Q30370672 | Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target |
| Q46943466 | Increase in serum resistin during weight loss in overweight subjects is related to lipid metabolism. |
| Q51360671 | Increased apoB/A-I ratio independently associated with Type 2 diabetes mellitus: cross-sectional study in a Korean population. |
| Q46880764 | Increasing evidence-based treatments to reduce coronary heart disease mortality in Sweden: quantifying the potential gains |
| Q40329911 | Inflammatory effects of very low-density lipoprotein and fatty acids |
| Q42906629 | Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS) |
| Q35075040 | Integrated role of two apoliprotein E polymorphisms on apolipoprotein B levels and coronary artery disease in a biethnic population |
| Q51652663 | Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial |
| Q44913553 | Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction |
| Q39723364 | Interfacial interactions of apolipoprotein AI and high density lipoprotein: overlooked phenomena in blood-material contact |
| Q35763059 | Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part II: what do I tell my patients? |
| Q36455879 | Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease |
| Q36909373 | Iron metabolism and risk of cancer in the Swedish AMORIS study |
| Q81557066 | Is it time to discard the apo B:apo A-I ratio as a predictor of cardiovascular disease? |
| Q36011273 | Is the ratio of apoB/apoA-1 the best predictor for the severity of coronary artery lesions in Chinese diabetics with stable angina pectoris? An assessment based on Gensini scores |
| Q51702589 | Korean traditional Chungkookjang improves body composition, lipid profiles and atherogenic indices in overweight/obese subjects: a double-blind, randomized, crossover, placebo-controlled clinical trial. |
| Q34997089 | LDL cholesterol estimation in patients with the metabolic syndrome |
| Q37734181 | Levels of Apolipoprotein A1, B100 and Lipoprotein (a) in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People |
| Q44368437 | Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin |
| Q51105427 | Lipid and lipoprotein abnormalities in acute lymphoblastic leukemia survivors. |
| Q37833906 | Lipid parameters for measuring risk of cardiovascular disease |
| Q28385524 | Lipid profiles and the risk of endometrial cancer in the Swedish AMORIS study |
| Q28654304 | Lipid-related markers and cardiovascular disease prediction |
| Q35638659 | Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis |
| Q90711905 | Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis |
| Q28287744 | Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study |
| Q64125281 | Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review |
| Q92990898 | Lipoprotein Lipase Inhibitor, Nordihydroguaiaretic Acid, Aggravates Metabolic Phenotypes and Alters HDL Particle Size in the Western Diet-Fed db/db Mice |
| Q43267496 | Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). |
| Q34990605 | Lipoprotein heterogeneity: diagnostic and therapeutic implications |
| Q37146755 | Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women |
| Q46152808 | Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL). |
| Q38984136 | Lipoprotein profile and prevalence of cardiovascular risk factors in urban Moroccan women. |
| Q38754889 | Lipoprotein ratios are better than conventional lipid parameters in predicting arterial stiffness in young men. |
| Q82420242 | Lipoproteins and the Development of Restenosis After Stent Implantation in the Superficial Femoral Artery in Patients with Peripheral Artery Disease |
| Q37337498 | Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins |
| Q87356674 | Low Prevalence of Elevated ApoB Levels in Patients with Type 2 Diabetes Not Receiving Lipid-Lowering Therapy |
| Q37736741 | Low apoA-I is associated with insulin resistance in patients with impaired glucose tolerance: a cross-sectional study |
| Q21245697 | Low density lipoprotein cholesterol is inversely correlated with abdominal visceral fat area: a magnetic resonance imaging study |
| Q58813396 | Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study |
| Q37623115 | Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease |
| Q35771393 | Major lipids, apolipoproteins, and risk of vascular disease |
| Q37234311 | Marital status, education, and risk of acute myocardial infarction in Mainland China: the INTER-HEART study |
| Q34990610 | Measurement issues related to lipoprotein heterogeneity |
| Q92131505 | Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis |
| Q35935362 | Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study |
| Q37343671 | Metabolic syndrome and cardiovascular disease in South Asians |
| Q92689387 | Milk polar lipids reduce lipid cardiovascular risk factors in overweight postmenopausal women: towards a gut sphingomyelin-cholesterol interplay |
| Q46848307 | Minor changes in blood lipids after 6 weeks of high-volume low- intensity physical activity with strict energy balance control |
| Q45852208 | Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. |
| Q44564480 | Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis |
| Q37115301 | Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy |
| Q46166109 | Multiple lipid scoring system for prediction of coronary heart disease risk: application to African Americans |
| Q33902640 | Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction |
| Q43506496 | Negative correlation between serum syndecan-1 and apolipoprotein A1 in patients with type 2 diabetes mellitus |
| Q28392470 | Neighborhood Socioeconomic Status in Relation to Serum Biomarkers in the Black Women's Health Study |
| Q39383777 | Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study |
| Q34668335 | Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence |
| Q36202132 | Non-high-density lipoprotein cholesterol: why lower is better |
| Q34996036 | Nontraditional risk factors for cardiovascular disease and visceral adiposity index among different body size phenotypes |
| Q36300187 | Obesity and lipids |
| Q57117972 | Offspring’s blood pressure and metabolic phenotype after exposure to gestational hypertension in utero |
| Q37101182 | Omega-3 polyunsaturated fatty acid profiles and relationship with cardiometabolic risk factors in Cree (Eeyouch) of Northern Québec |
| Q24626884 | Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk |
| Q36623110 | Pathogenesis and treatment of diabetic vascular disease - illustrated by two cases |
| Q37782563 | Pharmacomodulation of High-Density Lipoprotein Metabolism as a Therapeutic Intervention for Atherosclerotic Disease |
| Q44445617 | Physical performance measures as a useful indicator of multiple geriatric syndromes in women aged 75 years and older |
| Q46817499 | Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes |
| Q43035689 | Plasma apo/lipoproteins disturbances as a precondition for metabolic syndrome in HCV seronegative heroin addicts |
| Q35762030 | Plasma apolipoproteins and risk for age related maculopathy |
| Q45155125 | Plasma kinetics of a cholesterol-rich microemulsion in subjects with heterozygous beta-thalassemia |
| Q52582466 | Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease. |
| Q54568621 | Potential implications of the choice among three alternative treatment targets for apolipoprotein B100 in the management of patients with type 2 diabetes and chronic kidney disease. |
| Q38613657 | Prediction of future cardiovascular disease with an equation to estimate apolipoprotein B in patients with high cardiovascular risk: an analysis from the TNT and IDEAL study |
| Q34427908 | Prediction of risk factors for coronary heart disease using Framingham Risk Score in Korean men. |
| Q54979003 | Preoperative apolipoprotein B/apolipoprotein A1 ratio: a novel prognostic factor for gastric cancer. |
| Q36494412 | Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes |
| Q42861251 | Prevalence of Hyperapolipoprotein B and Associations with Other Cardiovascular Risk Factors Among Human Immunodeficiency Virus–Infected Patients in Pernambuco, Brazil |
| Q34998823 | Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome |
| Q40458731 | Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. |
| Q35563676 | Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL |
| Q37494202 | Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review |
| Q58813397 | Prostate cancer risk in the Swedish AMORIS study |
| Q37456214 | Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker. |
| Q84577220 | Prothrombotic markers in asymptomatic dyslipidemic subjects |
| Q37135042 | Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia |
| Q28541818 | Reduced apolipoprotein glycosylation in patients with the metabolic syndrome |
| Q35916568 | Reduced cardiovascular risk after bariatric surgery is linked to plasma ceramides, apolipoprotein-B100, and ApoB100/A1 ratio |
| Q36443768 | Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians |
| Q37521966 | Reference interval determination of total plasma homocysteine in an Indian population |
| Q36262966 | Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh |
| Q36007212 | Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies |
| Q36054342 | Relation of Combined Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B With Atherosclerosis in Adults With Type 1 Diabetes Mellitus |
| Q58690451 | Relation of High-Density Lipoprotein Cholesterol and Apoprotein A1 Levels with Presence and Severity of Coronary Obstruction |
| Q36262987 | Relationship between PON1L55M and Q192R gene polymorphisms and high APO B/APO A-I ratios |
| Q41894412 | Relationship between hyperuricemia and lipid profiles in US adults. |
| Q34009628 | Relationship between serum lipid values and atherosclerotic burden in the proximal thoracic aorta |
| Q46734939 | Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). |
| Q44242893 | Risk factors for coronary heart disease in 55- and 35-year-old men and women in Sweden and Estonia |
| Q53149258 | Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. |
| Q37973386 | Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques |
| Q43932707 | Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study |
| Q35070738 | Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). |
| Q35904825 | Role of fibric acid derivatives in the management of risk factors for coronary heart disease |
| Q35188947 | Role of lipid and lipoprotein profiles in risk assessment and therapy. |
| Q37181620 | Role of the APOB Gene Polymorphism (c.12669G>A, p. Gln4154Lys) in Coronary Artery Disease in the Indian Punjabi Population |
| Q46495908 | Role of the fractalkine receptor CX3CR1 polymorphisms V249I and T280M as risk factors for early-onset coronary artery disease in patients with no classic risk factors. |
| Q36798470 | Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes--a prospective observational cohort study. |
| Q37603797 | Serum Apo A-1 and Its Role as a Biomarker of Coronary Artery Disease |
| Q90413938 | Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study |
| Q50318500 | Serum Lipid Alterations in Early Rheumatoid Arthritis Patients on Disease Modifying Anti Rheumatoid Therapy |
| Q36219627 | Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study |
| Q64890713 | Serum Uric Acid in Roma and Non-Roma-Its Correlation with Metabolic Syndrome and Other Variables. |
| Q50061267 | Serum apolipoprotein B is inversely associated with eccentric left ventricular hypertrophy in peritoneal dialysis patients |
| Q79771911 | Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation |
| Q36392380 | Serum apolipoproteins in relation to intakes of fish in population of Arkhangelsk County |
| Q58813375 | Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study |
| Q34833951 | Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study |
| Q37562638 | Serum concentrations of cholesterol, apolipoprotein A-I and apolipoprotein B in a total of 1694 meat-eaters, fish-eaters, vegetarians and vegans |
| Q40258867 | Serum inflammatory markers and colorectal cancer risk and survival |
| Q37277947 | Serum lipid profile constituents as markers of cardiovascular morbidity in patients on chronic hemodialysis. |
| Q33760061 | Serum lipids, apolipoproteins, and mortality among coronary artery disease patients |
| Q64247351 | Sleep duration and apolipoprotein B in metabolically healthy and unhealthy overweight/obese phenotypes: a cross-sectional study in Chinese adults |
| Q37180162 | Statin treatment in the elderly: how much do we know? |
| Q35967383 | Statins: can the new generation make an impression? |
| Q46942491 | Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study |
| Q34695851 | Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. |
| Q38980545 | The AMORIS cohort |
| Q39923045 | The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population |
| Q31129827 | The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases |
| Q37156072 | The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk |
| Q37311116 | The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient |
| Q36455901 | The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence |
| Q35234169 | The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity |
| Q40174512 | The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort |
| Q42366242 | The association between the apolipoprotein B/A-I ratio and coronary calcification may differ depending on kidney function in a healthy population. |
| Q37107485 | The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment |
| Q64965444 | The effect of hormone therapy on bone mineral density and cardiovascular factors among Iranian female athletes with amenorrhea/oligomenorrhea: A randomized clinical trial. |
| Q35191722 | The effect of physical exercise on reverse cholesterol transport |
| Q35233375 | The effect of the addition of resistance training to a dietary education intervention on apolipoproteins and diet quality in overweight and obese older adults |
| Q83621530 | The effects of resistance training on ApoB/ApoA-I ratio, Lp(a) and inflammatory markers in patients with type 2 diabetes |
| Q46973476 | The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes |
| Q38794761 | The efficacy of evolocumab in the management of hyperlipidemia: a systematic review |
| Q35848359 | The evolution and refinement of traditional risk factors for cardiovascular disease |
| Q34564466 | The impact of plasma triglyceride and apolipoproteins concentrations on high-density lipoprotein subclasses distribution |
| Q37902963 | The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk |
| Q37167521 | The independent relationship between triglycerides and coronary heart disease. |
| Q58813379 | The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study |
| Q87548200 | The ratio of high-density lipoprotein cholesterol to apolipoprotein A-I predicts myocardial injury following elective percutaneous coronary intervention |
| Q37900093 | The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations |
| Q34267570 | The relationship between high density lipoprotein subclass profile and plasma lipids concentrations |
| Q36982574 | The treatment of dyslipidemia--what's left in the pipeline? |
| Q41203206 | The utility of the apolipoprotein A1 remnant ratio in predicting incidence coronary heart disease in a primary prevention cohort: The Jackson Heart Study |
| Q33697095 | The value of Apolipoprotein B/Apolipoprotein A1 ratio for metabolic syndrome diagnosis in a Chinese population: a cross-sectional study |
| Q53392636 | The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population. |
| Q30650408 | The water-soluble inclusion complex of ilexgenin A with β-cyclodextrin polymer--a novel lipid-lowering drug candidate |
| Q47109213 | Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. |
| Q34270559 | Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula |
| Q58052232 | Tumor necrosis factor receptor 2 M196R polymorphism in rheumatoid arthritis and osteoarthritis: relationship with sTNFR2 levels and clinical features |
| Q38473935 | Unfavorable lipoprotein profile in childhood cancer survivors with suprasellar brain tumors--a high Apo B level and increased small dense LDL-cholesterol |
| Q45948035 | Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). |
| Q35007779 | Use of lipoprotein particle measures for assessing coronary heart disease risk post-American Heart Association/American College of Cardiology guidelines: the Multi-Ethnic Study of Atherosclerosis. |
| Q43260313 | Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes |
| Q44384629 | Usefulness of non-high-density lipoprotein cholesterol determinations in the diagnosis and treatment of dyslipidemia |
| Q33820011 | Using apolipoprotein B to manage dyslipidemic patients: time for a change? |
| Q37082701 | Variations in HDL-carried miR-223 and miR-135a concentrations after consumption of dietary trans fat are associated with changes in blood lipid and inflammatory markers in healthy men - an exploratory study. |
| Q40391448 | Vascular risk factors in INPH: A prospective case-control study (the INPH-CRasH study). |
| Q80166350 | Which lipid measures are prognostic indicators of cardiovascular disease in women? |
| Q42523430 | Zinc depletion reduced Egr-1 and HNF-3beta expression and apolipoprotein A-I promoter activity in Hep G2 cells |
| Q88585722 | [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease] |
| Q53556272 | [Impact of both cardiac-CT and cardiac-MR on the assessment of coronary risk]. |
Search more.